These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Long-term use of hydroxyurea for sickle cell anemia. Hagar W JAMA; 2003 Aug; 290(6):753; author reply 754. PubMed ID: 12915424 [No Abstract] [Full Text] [Related]
23. Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia. Zahr RS; Hankins JS; Kang G; Li C; Wang WC; Lebensburger J; Estepp JH Am J Hematol; 2019 Jan; 94(1):E27-E29. PubMed ID: 30359463 [No Abstract] [Full Text] [Related]
24. Hydroxyurea therapy: improving the lives of patients with sickle cell disease. Anderson N Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291 [TBL] [Abstract][Full Text] [Related]
25. Hydroxyurea and sickle cell disease: a chance for every patient. Weiner DL; Brugnara C JAMA; 2003 Apr; 289(13):1692-4. PubMed ID: 12672739 [No Abstract] [Full Text] [Related]
27. Hydroxyurea and new agents for the treatment of sickle cell disease. Rodgers GP Clin Adv Hematol Oncol; 2004 Nov; 2(11):713-5. PubMed ID: 16163257 [No Abstract] [Full Text] [Related]
28. Experts urge wider use of hydroxyurea for sickle cell disease. Traynor K Am J Health Syst Pharm; 2008 Apr; 65(7):592-3. PubMed ID: 18359960 [No Abstract] [Full Text] [Related]
29. Hydroxycarbamide use in young children with sickle-cell anaemia. Takahashi Y; Mori J; Tsubokura M; Matsumura T; Kami M Lancet; 2011 Nov; 378(9805):1777. PubMed ID: 22098851 [No Abstract] [Full Text] [Related]
30. Hydroxycarbamide use in young children with sickle-cell anaemia. Obaro SK; Inusa B; Telfer P Lancet; 2011 Nov; 378(9805):1777. PubMed ID: 22098850 [No Abstract] [Full Text] [Related]
32. Lung function decline in children with sickle cell disease treated with hydroxyurea. Seidl E; Wilson D; Odame I; Kirby-Allen M; Grasemann H Am J Hematol; 2024 Jan; 99(1):E19-E21. PubMed ID: 37859529 [No Abstract] [Full Text] [Related]
34. Hydroxyurea for sickle cell anemia. Bachmeyer C; Aractingi S; Lionnet F N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18609755 [No Abstract] [Full Text] [Related]
35. European register of patients with sickle cell disease treated with hydroxyurea is being set up. Davies SC; Roberts-Harwood M BMJ; 1998 Aug; 317(7157):541-2. PubMed ID: 9712619 [No Abstract] [Full Text] [Related]
36. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea. Stettler N; McKiernan CM; Melin CQ; Adejoro OO; Walczak NB JAMA; 2015 Apr; 313(16):1671-2. PubMed ID: 25919532 [No Abstract] [Full Text] [Related]
37. Building capacity to reduce stroke in children with sickle cell anemia in the Dominican Republic: the SACRED trial. Sánchez LM; Nieves RM; Latham T; Stuber S; Luden JR; Urcuyo GS; Berges ME; Florencio C; Gonzalez C; Del Villar P; Lane A; Schultz W; Jeste N; Mena R; Ware RE Blood Adv; 2018 Nov; 2(Suppl 1):50-53. PubMed ID: 30504201 [No Abstract] [Full Text] [Related]
38. The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease. Puffer E; Schatz J; Roberts CW Child Neuropsychol; 2007 Mar; 13(2):142-54. PubMed ID: 17364571 [TBL] [Abstract][Full Text] [Related]
39. Hydroxyurea use in patients with sickle cell disease in a Medicaid population. Ritho J; Liu H; Hartzema AG; Lottenberg R Am J Hematol; 2011 Oct; 86(10):888-90. PubMed ID: 21922530 [No Abstract] [Full Text] [Related]